Finance

Beta
Lists
DMYD-B:STO
Diamyd Medical AB
SEK 1.09
+1.87%
(+0.020) 1D
Jul 3, 5:29:51 PM GMT+2  ·   SEK
All symbols
SymbolPriceChange% Change
Generating top insights for DMYD-B...
Open
SEK 1.07
High
SEK 1.14
Low
SEK 1.05
Mkt. cap
165.11M
Avg. vol.
939.12K
Volume
769.45K
52-wk high
SEK 17.88
52-wk low
SEK 0.90
EPS
-SEK 1.98
Shares outstanding
134.00M
No. of employees
44
Open
SEK 1.07
High
SEK 1.14
Low
SEK 1.05
Mkt. cap
165.11M
Avg. vol.
939.12K
Volume
769.45K
52-wk high
SEK 17.88
52-wk low
SEK 0.90
EPS
-SEK 1.98
Shares outstanding
134.00M
No. of employees
44
News stories
From sources across the web
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products. The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB
CEOUlf Hannelius
Employees44
Founded1984
Headquarters-
SectorBiotechnology
Websitediamyd.com
Previous reportsAll values in SEK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SEK
Aug 2025
Nov 2025
Feb 2026
May 2026
Revenue
19.00K
245.00K
99.00K
70.00K
Cost of goods sold
718.00K
938.00K
786.00K
964.00K
Cost of revenue
718.00K
938.00K
786.00K
964.00K
Research and development expenses
30.48M
30.47M
45.09M
105.01M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14.12M
16.82M
18.30M
19.43M
Operating expense
45.81M
48.14M
64.34M
126.30M
Total operating expenses
46.53M
49.08M
65.12M
127.27M
Operating income
-46.51M
-48.84M
-65.02M
-127.20M
Other non operating income
-3.00K
1.00K
1.00K
-
EBT including unusual items
-44.86M
-48.84M
-62.88M
-127.06M
EBT excluding unusual items
-44.86M
-48.06M
-62.88M
-127.06M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-536.00K
-925.00K
-840.00K
137.00K
Net income
-44.86M
-48.84M
-62.88M
-127.06M
Net profit margin
-236,126.32%
-19,936.33%
-63,513.13%
-181,514.29%
Earnings per share
-
-
-
-
Interest and investment income
3.70M
833.00K
2.78M
1.07M
Interest expense
-6.21M
-62.00K
-635.00K
-930.00K
Net interest expenses
-2.51M
771.00K
2.14M
138.00K
Depreciation and amortization charges
1.76M
1.78M
1.78M
1.73M
EBITDA
-44.87M
-47.06M
-63.24M
-125.47M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer